Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

the EUMDS Registry Participants

Research output: Contribution to journalArticlepeer-review

12 Scopus citations
Original languageEnglish
Pages (from-to)1745-1750
Number of pages6
Issue number6
StatePublished - Jun 2021
Externally publishedYes

Bibliographical note

Funding Information:
Infirmary, Aberdeen, UK; 148Queen Elizabeth Hospital, Birmingham, UK; 149Blackpool Victoria Hospital, Blackpool, UK; 150Royal Bournemouth Hospital, Bournemouth, UK; 151Bradford Royal Infirmary, Bradford, UK; 152Addenbrooke’s Hospital, Cambridge, UK; 153Western Infirmary, Glasgow, UK; 154Harrogate District Hospital, Harrogate, UK; 155Huddersfield Royal Infirmary, Huddersfield, UK; 156Hull and East Yorkshire Hospitals NHS Trust, Hull, UK; 157Leeds Teaching Hospitals, Leeds, UK; 158Christie Hospital, Manchester, UK; 159Royal Victoria Infirmary, Newcastle upon Tyne, UK; 160Northampton General Hospital, Northampton, UK; 161City Hospital, Nottingham, UK; 162John Radcliffe Hospitals NHS Trust, Oxford, UK; 163Airedale NHS Trust, Steeton, UK; 164Royal Cornwall Hospital, Truro, UK; 165Mid Yorkshire Hospitals, Wakefield, UK; 166Worcestershire Acute Hospitals NHS Trust, Worcester, UK; 167York Hospital, York, UK Funding The EUMDS Registry is supported by an educational grant from Novartis Pharmacy B.V. Oncology Europe, and Amgen Limited. This work is part of the MDS-RIGHT activities, which has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 634789 MDS-RIGHT—“Providing the right care to the right patient with Myelo-Dysplastic Syndrome at the right time.” The Lifelines Biobank initiative has been made possible by subsidy from the Dutch Ministry of Health, Welfare and Sport, the Dutch Ministry of Economic Affairs, the University Medical Center Groningen (UMCG the Netherlands), University Groningen, and the Northern Provinces of the Netherlands. The authors wish to acknowledge the services of the Lifelines Cohort Study, the contributing research centers delivering data to Lifelines, and all the study participants.

Funding Information:
Conflict of interest CvM: project manager of the EUMDS Registry, is funded by the EUMDS and MDS-RIGHT project budget; ASm: research funding from Novartis, Cilag-Janssen, and Boehringer Ingelheim; ASy: honoraria and consulting fees from Amgen, Celgene/ GenesisPharma, Genzyme/Sanofi, Gilead, Janssen-Cilag, Pfizer, MSD, and Novartis; HG: honoraria from Celgene, Novartis, and Alexion; SK: honoraria from Novartis, Jazz, and Celgene; EH-L: research funding from Celgene; NB: research funding from Novartis, Bristol Meyer Squibb, Pfizer, Ariad, MSD, Astellas, Xenikos, and Celgene, educational grant from Novartis, Celgene, and Janssen-Cilag; DWS: paid employee of RadboudUMC, which offers hepcidin measurements via at a fee for service basis; TdW: research funding from Amgen, Celgene, and Novartis, as project coordinator EUMDS. The other authors declare that they have no conflict of interest.

Cite this